- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02693535
TAPUR: Tester bruken av Food and Drug Administration (FDA)-godkjente legemidler som retter seg mot en spesifikk abnormitet i et svulstgen hos personer med kreft i avansert stadium (TAPUR)
Studie for målrettet agent og profileringsbruksregister (TAPUR).
The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.
NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).
********************************************************************
Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.
********************************************************************
Studieoversikt
Status
Intervensjon / Behandling
- Legemiddel: Sunitinib (CLOSED TO ENROLLMENT)
- Legemiddel: Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT)
- Legemiddel: Vemurafenib and Cobimetinib (CLOSED TO ENROLLMENT)
- Legemiddel: Olaparib (CLOSED TO ENROLLMENT)
- Legemiddel: Nivolumab and Ipilimumab (CLOSED TO ENROLLMENT)
- Legemiddel: Abemaciclib (CLOSED TO ENROLLMENT)
- Legemiddel: Talazoparib (CLOSED TO ENROLLMENT)
- Legemiddel: Atezolizumab and Talazoparib (CLOSED TO ENROLLMENT)
- Legemiddel: Tucatinib plus Trastuzumab Subcutaneous (SC) (CLOSED TO ENROLLMENT)
- Legemiddel: Futibatinib
- Legemiddel: Dabrafenib plus Trametinib
- Legemiddel: Fam-Trastuzumab Deruxtecan-Nxki (TDxD)
Detaljert beskrivelse
The Targeted Agent and Profiling Utilization Registry (TAPUR) Study is a non-randomized clinical trial that aims to describe the safety and efficacy of commercially available, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic variant. TAPUR will study Food and Drug Administration (FDA)-approved targeted therapies that are contributed by collaborating pharmaceutical companies, catalogue the choice of molecular profiling test by clinical oncologists and develop hypotheses for additional clinical trials.
Studietype
Registrering (Antatt)
Fase
- Fase 2
Kontakter og plasseringer
Studiekontakt
- Navn: Laurie Smith, MA
- Telefonnummer: www.tapur.org
- E-post: tapur@asco.org
Studiesteder
-
-
Alabama
-
Birmingham, Alabama, Forente stater, 35294
- Rekruttering
- University of Alabama at Birmingham Comprehensive Cancer Center
-
Hovedetterforsker:
- Mehmet Akce, MD
-
Ta kontakt med:
- Kun Yuan
- Telefonnummer: 205-644-2584
- E-post: kunyuan@uabmc.edu
-
-
Arizona
-
Phoenix, Arizona, Forente stater, 85338
- Rekruttering
- Cancer Treatment Centers of America-Phoenix
-
Hovedetterforsker:
- Sagun Shrestha, MD
-
Ta kontakt med:
- Alex Lizzul
- Telefonnummer: 602-872-5654
- E-post: alizzul@coh.org
-
-
California
-
Auburn, California, Forente stater, 95602
- Rekruttering
- Sutter Auburn
-
Ta kontakt med:
- Kirsten Babski
- Telefonnummer: 916-878-4990
- E-post: BabskiK@sutterhealth.org
-
Hovedetterforsker:
- Nitin Rohatgi, MD
-
Berkeley, California, Forente stater, 94705
- Rekruttering
- Sutter Alta Bates
-
Ta kontakt med:
- Christopher Tang
- Telefonnummer: 510-204-3428
- E-post: Christopher.Tang@sutterhealth.org
-
Hovedetterforsker:
- Nitin Rohatgi, MD
-
Los Angeles, California, Forente stater, 90025
- Rekruttering
- The Angeles Clinic and Research Institute, A Cedars-Sinai Affiliate
-
Ta kontakt med:
- Teri Mata
- Telefonnummer: 310-231-2115
- E-post: tmata@theangelesclinic.org
-
Hovedetterforsker:
- Omid Hamid, MD
-
Oakland, California, Forente stater, 94611
- Rekruttering
- Kaiser Permanente - Oakland Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
Palo Alto, California, Forente stater, 94301
- Rekruttering
- Sutter Palo Alto Medical Foundation: Palo Alto
-
Ta kontakt med:
- E-post: clinicaltrials@pamf.org
-
Roseville, California, Forente stater, 95661
- Rekruttering
- Kaiser Permanente - Roseville Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
Roseville, California, Forente stater, 95661
- Rekruttering
- Sutter Roseville
-
Ta kontakt med:
- Kirsten Babski
- Telefonnummer: 916-878-4990
- E-post: BabskiK@sutterhealth.org
-
Hovedetterforsker:
- Nitin Rohatgi, MD
-
Sacramento, California, Forente stater, 95814
- Rekruttering
- Kaiser Permanente - Sacramento Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
Sacramento, California, Forente stater, 95816
- Rekruttering
- Sutter Sacramento
-
Ta kontakt med:
- E-post: SIMR@sutterhealth.org
-
Hovedetterforsker:
- Nitin Rohatgi, MD
-
San Francisco, California, Forente stater, 94115
- Rekruttering
- California Pacific Medical Center Research Institute
-
Ta kontakt med:
- Telefonnummer: 415-600-1654
- E-post: clinicalresearch@sutterhealth.org
-
Hovedetterforsker:
- Nitin Rohatgi, MD
-
San Francisco, California, Forente stater, 94080
- Rekruttering
- Kaiser Permanente - South San Francisco Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
San Francisco, California, Forente stater, 94115
- Rekruttering
- Kaiser Permanente - San Francisco Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
San Francisco, California, Forente stater, 94115
- Rekruttering
- Sutter Cancer Research Consortium
-
Ta kontakt med:
- Laurel Brechtel
- Telefonnummer: 415-600-1654
- E-post: BrechtLa@cpmcri.org
-
Hovedetterforsker:
- Stacy D'Andre, MD
-
San Jose, California, Forente stater, 95119
- Rekruttering
- Kaiser Permanente - San Jose Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
San Leandro, California, Forente stater, 94577
- Rekruttering
- Kaiser Permanente - San Leandro Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
Santa Barbara, California, Forente stater, 93105
- Rekruttering
- Sutter Sansum Clinic
-
Hovedetterforsker:
- Nitin Rohatgi, MD
-
Ta kontakt med:
- Selina Perez
- Telefonnummer: 831-458-5837
- E-post: Selina.Perez@sutterhealth.org
-
Santa Clara, California, Forente stater, 95051
- Rekruttering
- Kaiser Permanente - Santa Clara Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
Santa Cruz, California, Forente stater, 95065
- Rekruttering
- Sutter Palo Alto Medical Foundation: Santa Cruz
-
Ta kontakt med:
- E-post: clinicaltrials@pamf.org
-
Santa Cruz, California, Forente stater, 994538
- Rekruttering
- Sutter Palo Alto Medical Foundation: Fremont
-
Ta kontakt med:
- E-post: clinicaltrials@pamf.org
-
Sunnyvale, California, Forente stater, 94086
- Rekruttering
- Sutter Palo Alto Medical Foundation: Sunnyvale
-
Ta kontakt med:
- E-post: clinicaltrials@pamf.org
-
Vallejo, California, Forente stater, 94589
- Rekruttering
- Kaiser Permanente - Vallejo Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M. Suga, MD
-
Walnut Creek, California, Forente stater, 94596
- Rekruttering
- Kaiser Permanente - Walnut Creek Medical Center
-
Ta kontakt med:
- Desiree Goldstein
- E-post: desiree.goldstein@kp.org
-
Hovedetterforsker:
- Jennifer M Suga, MD
-
-
Connecticut
-
Bridgeport, Connecticut, Forente stater, 06606
- Rekruttering
- Saint Vincent's Medical Center (SVMC)
-
Ta kontakt med:
- Telefonnummer: 860-972-4700
- E-post: CancerResearchSupport@hhchealth.org
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
Hartford, Connecticut, Forente stater, 06102
- Rekruttering
- Hartford Hospital
-
Ta kontakt med:
- Telefonnummer: 860-972-4700
- E-post: CancerResearchSupport@hhchealth.org
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
Meriden, Connecticut, Forente stater, 06451
- Rekruttering
- Midstate Medical Center (MSMC)
-
Ta kontakt med:
- Telefonnummer: 860-972-4700
- E-post: CancerResearchSupport@hhchealth.org
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
New Britain, Connecticut, Forente stater, 06053
- Rekruttering
- The Hospital of Central Connecticut (HOCC) Cancer Center
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
Ta kontakt med:
- Telefonnummer: 8609724700
- E-post: CancerResearchSupport@hhchealth.org
-
Norwich, Connecticut, Forente stater, 06360
- Rekruttering
- William W. Backus Hospital
-
Ta kontakt med:
- Telefonnummer: 860-972-4700
- E-post: CancerResearchSupport@hhchealth.org
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
Torrington, Connecticut, Forente stater, 06790
- Rekruttering
- Charlotte Hungerford
-
Ta kontakt med:
- Telefonnummer: 860-972-4700
- E-post: CancerResearchSupport@hhchealth.org
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
Willimantic, Connecticut, Forente stater, 06226
- Rekruttering
- Windham Hospital (WH)
-
Ta kontakt med:
- Telefonnummer: 860-972-4700
- E-post: CancerResearchSupport@hhchealth.org
-
Hovedetterforsker:
- Wylie Hosmer, MD
-
-
Florida
-
Altamonte Springs, Florida, Forente stater, 32701
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Aventura, Florida, Forente stater, 33180
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Aventura
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Bonita Springs, Florida, Forente stater, 34135
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Bradenton, Florida, Forente stater, 34211
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Brandon, Florida, Forente stater, 33511
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Cape Coral, Florida, Forente stater, 33909
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Clearwater, Florida, Forente stater, 33761
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Coral Gables, Florida, Forente stater, 33146
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Lennar
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Deerfield Beach, Florida, Forente stater, 33442
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Deerfield Beach
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Fort Lauderdale, Florida, Forente stater, 33308
- Rekruttering
- Holy Cross Hospital
-
Hovedetterforsker:
- Zdenka Segota, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Fort Myers, Florida, Forente stater, 33901
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Forente stater, 33905
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Fort Myers, Florida, Forente stater, 33908
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Gainesville, Florida, Forente stater, 32610
- Rekruttering
- University of Florida Health
-
Hovedetterforsker:
- Thomas George, MD
-
Ta kontakt med:
- Anna Kukulka, RN, BSN
- Telefonnummer: 352-293-2551
- E-post: akukulka@ufl.edu
-
Gainesville, Florida, Forente stater, 32605
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Largo, Florida, Forente stater, 33770
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Lecanto, Florida, Forente stater, 34461
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami Sylvester Comprehensive Cancer Center
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Alex's Place
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forente stater, 33136
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Griffin Cancer Research Building
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forente stater, 33176
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Kendall
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Miami, Florida, Forente stater, 33181
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Sole Mia
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Naples, Florida, Forente stater, 34102
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Ocala, Florida, Forente stater, 34474
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orange City, Florida, Forente stater, 32763
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Orlando, Florida, Forente stater, 32806
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Plantation, Florida, Forente stater, 33324
- Rekruttering
- University of Miami/Sylvester Cancer Institute - Plantation
-
Ta kontakt med:
- Carolina Troche, BS
- Telefonnummer: 305-243-1481
- E-post: cxt582@med.miami.edu
-
Hovedetterforsker:
- Carmen Calfa, MD
-
Port Charlotte, Florida, Forente stater, 33980
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Forente stater, 34236
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Sarasota, Florida, Forente stater, 34239
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
St. Petersburg, Florida, Forente stater, 33701
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tampa, Florida, Forente stater, 33607
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Tavares, Florida, Forente stater, 32778
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
The Villages, Florida, Forente stater, 32159
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Trinity, Florida, Forente stater, 34655
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
Venice, Florida, Forente stater, 34285
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Venice, Florida, Forente stater, 34292
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists South / Sarah Cannon Research Institute
-
Winter Park, Florida, Forente stater, 32789
- Aktiv, ikke rekrutterende
- Florida Cancer Specialists North / Sarah Cannon Research Institute
-
-
Georgia
-
Atlanta, Georgia, Forente stater, 30322
- Rekruttering
- Emory University Winship Cancer Institute
-
Hovedetterforsker:
- Olatunji Alese, MD
-
Ta kontakt med:
- Krystal Bagley
- Telefonnummer: 404-778-8670
- E-post: krystal.joi.bagley@emory.edu
-
Atlanta, Georgia, Forente stater, 30265
- Rekruttering
- Cancer Treatment Centers of America - Atlanta
-
Hovedetterforsker:
- Bamidele Adesunloye, MD
-
Ta kontakt med:
- Elizabeth McKoy, RN, BSN
- Telefonnummer: 770-400-7177
- E-post: emckoy@coh.org
-
Savannah, Georgia, Forente stater, 31405
- Rekruttering
- Summit Cancer Care
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 9128195723
- E-post: smiths1@sjchs.org
-
Savannah, Georgia, Forente stater, 31405
- Rekruttering
- Gynecologic Oncology and Surgical Specialists at the Lewis Cancer & Research Pavilion
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 9128195723
- E-post: smiths1@sjchs.org
-
Savannah, Georgia, Forente stater, 31405
- Rekruttering
- Lewis Cancer & Research Pavilion at the Melanoma, Skin Cancer & Sarcoma Institute
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-post: smiths1@sjchs.org
-
Savannah, Georgia, Forente stater, 31405
- Rekruttering
- Lewis Cancer & Research Pavilion
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 912-819-5723
- E-post: smiths1@sjchs.org
-
Hovedetterforsker:
- Mark Taylor, MD
-
-
Hawaii
-
Honolulu, Hawaii, Forente stater, 96813
- Rekruttering
- The Queen's Medical Center - POB I
-
Hovedetterforsker:
- Jared Acoba, MD
-
Ta kontakt med:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-post: tkelleher@queens.org
-
Honolulu, Hawaii, Forente stater, 96813
- Rekruttering
- The Queen's Medical Center - Punchbowl
-
Hovedetterforsker:
- Jared Acoba, MD
-
Ta kontakt med:
- Tim Kelleher
- Telefonnummer: 808 691-8582
- E-post: tkelleher@queens.org
-
Honolulu, Hawaii, Forente stater, 96817
- Rekruttering
- The Queen's Medical Center - Kuakini
-
Hovedetterforsker:
- Jared Acoba, MD
-
Ta kontakt med:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-post: tkelleher@queens.org
-
‘Ewa Beach, Hawaii, Forente stater, 96706
- Rekruttering
- The Queen's Medical Center - West Oahu
-
Hovedetterforsker:
- Jared Acoba, MD
-
Ta kontakt med:
- Tim Kelleher
- Telefonnummer: 8086918582
- E-post: tkelleher@queens.org
-
-
Illinois
-
Chicago, Illinois, Forente stater, 60099
- Rekruttering
- Cancer Treatment Centers of America-Chicago
-
Hovedetterforsker:
- Evan Pisick, MD
-
Ta kontakt med:
- Office of Clinical Trials
- Telefonnummer: 847-731-1777
- E-post: CHIResearch@coh.org
-
-
Indiana
-
Indianapolis, Indiana, Forente stater, 46250
- Rekruttering
- Community Health Network (The University of Texas MD Anderson Cancer Center)
-
Hovedetterforsker:
- Funda Meric-Bernstam, MD
-
Ta kontakt med:
- Kshipra Sharma, MPH, MS
- Telefonnummer: 713-745-8431
- E-post: Ksharma2@MDAnderson.org
-
-
Maine
-
Augusta, Maine, Forente stater, 04330
- Rekruttering
- Harold Alfond Center for Cancer Care
-
Ta kontakt med:
- Sandra Neptune, BSN, RN
- Telefonnummer: 207-626-4811
- E-post: sandra.neptune@mainegeneral.org
-
Hovedetterforsker:
- Lindsay Hathaway, MD
-
Augusta, Maine, Forente stater, 04330
- Rekruttering
- Jackson Laboratory - Maine Cancer Genomics Initiative
-
Ta kontakt med:
- Petra Helbig, CCRP
- Telefonnummer: 207-664-4659
- E-post: Petra.Helbig@jax.org
-
Hovedetterforsker:
- Jens Rueter, MD
-
Belfast, Maine, Forente stater, 04915
- Rekruttering
- Waldo County General Hospital
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Biddeford, Maine, Forente stater, 04005
- Rekruttering
- SMHC Cancer Care and Blood Disorders -Biddeford
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Brewer, Maine, Forente stater, 04412
- Rekruttering
- Northern Light Cancer Care
-
Hovedetterforsker:
- Sarah Sinclair, MD
-
Ta kontakt med:
- Carla Mancini, MHA, BSN, RN
- Telefonnummer: 207-973-5581
- E-post: cmancini@northernlight.org
-
Brewer, Maine, Forente stater, 04412
- Rekruttering
- Raish Peavey Haskell Children's Cancer and Treatment Center
-
Hovedetterforsker:
- Sarah Sinclair, MD
-
Ta kontakt med:
- Carla C Mancini, RN, BSN, OCN
- Telefonnummer: 2079735581
- E-post: cmancini@northernlight.org
-
Brunswick, Maine, Forente stater, 04011
- Rekruttering
- MaineHealth Cancer Care -Brunswick
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Kennebunk, Maine, Forente stater, 04043
- Rekruttering
- New England Cancer Specialist
-
Hovedetterforsker:
- Christian Thomas, MD
-
Ta kontakt med:
- Patricia C Collins
- Telefonnummer: 2073033422
- E-post: collip@newecs.org
-
Kittery, Maine, Forente stater, 03904
- Rekruttering
- York Hopsital Oncology & Infusion Care in Kittery
-
Hovedetterforsker:
- Marilyn McLaughlin, MD
-
Ta kontakt med:
- Brenda i Kiberd, RN
- Telefonnummer: 2073616115
- E-post: Brenda.Kiberd@yorkhospital.com
-
Norway, Maine, Forente stater, 04268
- Rekruttering
- Stephens Memorial Hospital
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Rockport, Maine, Forente stater, 04856
- Rekruttering
- Penobscot Bay Medical Center
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Sanford, Maine, Forente stater, 04073
- Rekruttering
- SMHC Cancer Care and Blood Disorders -Sandford
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Scarborough, Maine, Forente stater, 04074
- Rekruttering
- Maine Children's Cancer Program
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Scarborough, Maine, Forente stater, 04074
- Rekruttering
- Maine Medical Partner's Women's Health
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Ta kontakt med:
- Jen - Dalton, MHA, BSN, RN
- Telefonnummer: 2072948291
- E-post: JDalton@mmc.org
-
Scarborough, Maine, Forente stater, 04074
- Rekruttering
- New England Cancer Specialist
-
Hovedetterforsker:
- Christian Thomas, MD
-
Ta kontakt med:
- Patricia Collins, BA, CCRC
- Telefonnummer: 207-303-3422
- E-post: collip@newecs.org
-
South Portland, Maine, Forente stater, 04106
- Rekruttering
- MaineHealth Cancer Care -South Portland
-
Ta kontakt med:
- Jen Dalton, MHA, BSN, RN
- Telefonnummer: 207-294-8291
- E-post: JDalton@mmc.org
-
Hovedetterforsker:
- Roger Inhorn, MD
-
Topsham, Maine, Forente stater, 04086
- Rekruttering
- New England Cancer Specialist
-
Hovedetterforsker:
- Christian Thomas, MD
-
Ta kontakt med:
- Patricia C Collins, BA, CCRC
- Telefonnummer: 12073033422
- E-post: collip@newecs.org
-
Wells, Maine, Forente stater, 04090
- Rekruttering
- York Hospital Oncology & Infusion Care in Wells
-
Hovedetterforsker:
- Marilyn McLaughlin, MD
-
Ta kontakt med:
- Brenda Kiberd, RN
- Telefonnummer: 207-361-6115
- E-post: Brenda.Kiberd@yorkhospital.com
-
York Village, Maine, Forente stater, 03909
- Rekruttering
- York Hospital Oncology & Infusion Care in York
-
Hovedetterforsker:
- Marilyn McLaughlin, MD
-
Ta kontakt med:
- Brenda i Kiberd, RN
- Telefonnummer: 2073616115
- E-post: Brenda.Kiberd@yorkhospital.com
-
-
Michigan
-
Ann Arbor, Michigan, Forente stater, 48109
- Aktiv, ikke rekrutterende
- University of Michigan
-
Ann Arbor, Michigan, Forente stater, 48106
- Rekruttering
- Trinity Health Ann Arbor Hospital
-
Hovedetterforsker:
- Elie Dib, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Detroit, Michigan, Forente stater, 48236
- Rekruttering
- Henry Ford Health Saint John Hospital
-
Hovedetterforsker:
- Carrie Dul, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Flint, Michigan, Forente stater, 48503
- Rekruttering
- Genesys Hurley Cancer Institute
-
Hovedetterforsker:
- Paul Adams, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Grand Rapids, Michigan, Forente stater, 49503
- Rekruttering
- Cancer Research Consortium of West Michigan
-
Ta kontakt med:
- Connie Szczepanek, RN
- Telefonnummer: 616-391-1230
- E-post: crcwm-regulatory@crcwm.org
-
Hovedetterforsker:
- Kathleen J. Yost, MD
-
Lansing, Michigan, Forente stater, 48912
- Rekruttering
- University of Michigan Health - Sparrow Lansing
-
Hovedetterforsker:
- Gordan Srkalovic, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Livonia, Michigan, Forente stater, 48154
- Rekruttering
- Trinity Health Livonia Hospital
-
Hovedetterforsker:
- Amit Mohindra, MD
-
Ta kontakt med:
- Telefonnummer: 7347127251
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Pontiac, Michigan, Forente stater, 48341
- Rekruttering
- Trinity Health Oakland Hospital
-
Hovedetterforsker:
- Julie Goodman, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Saginaw, Michigan, Forente stater, 48601
- Rekruttering
- MyMichigan Medical Center Saginaw
-
Hovedetterforsker:
- Nicholas Damico, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Traverse City, Michigan, Forente stater, 48341
- Rekruttering
- Michigan Cancer Research Consortium
-
Hovedetterforsker:
- Philip Stella, MD
-
Ta kontakt med:
- Beth LaVasseur, RN, MS
- Telefonnummer: 734-712-7251
- E-post: Beth.LaVasseur@stjoeshealth.org
-
Ta kontakt med:
- Telefonnummer: 877-590-5995
-
Warren, Michigan, Forente stater, 48093
- Rekruttering
- Henry Ford Health Warren Hospital
-
Hovedetterforsker:
- Carrie Dul, MD
-
Ta kontakt med:
- Telefonnummer: 7347123671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
-
Nebraska
-
Omaha, Nebraska, Forente stater, 68198
- Rekruttering
- University of Nebraska Medical Center
-
Hovedetterforsker:
- Alissa Marr, MD
-
Ta kontakt med:
- Micki Bethea, BS
- Telefonnummer: 402-559-8011
- E-post: mbethea@unmc.edu
-
-
New Hampshire
-
Concord, New Hampshire, Forente stater, 03103
- Rekruttering
- NH Oncology - Hematology, PA
-
Ta kontakt med:
- Ali Fleury
- Telefonnummer: 6033146888
- E-post: A.Fleury@nhoh.com
-
Hovedetterforsker:
- Michael Buff, MD
-
Manchester, New Hampshire, Forente stater, 03103
- Rekruttering
- Solinsky Center for Cancer Care
-
Ta kontakt med:
- Ali Fleury, BA, CCRP
- Telefonnummer: 603-314-6888
- E-post: A.Fleury@nhoh.com
-
Hovedetterforsker:
- Michael Buff, MD
-
Portsmouth, New Hampshire, Forente stater, 03801
- Rekruttering
- New England Cancer Specialist
-
Hovedetterforsker:
- Christian Thomas, MD
-
Ta kontakt med:
- Patricia C Collins, BA, CCRC
- Telefonnummer: 2073033422
- E-post: collip@newecs.org
-
-
New Mexico
-
Albuquerque, New Mexico, Forente stater, 87110
- Rekruttering
- Presbyterian Kaseman Hospital
-
Hovedetterforsker:
- Bernard Tawfik, MD
-
Ta kontakt med:
- Monique Robertson, RN
- Telefonnummer: (505)- 559-6100
- E-post: mrobertso2@phs.org
-
Albuquerque, New Mexico, Forente stater, 87102
- Rekruttering
- Lovelace Medical Center - Saint Joseph Square
-
Hovedetterforsker:
- Bernard Tawfik, MD
-
Ta kontakt med:
- Leslie Byatt
- Telefonnummer: (505) -925-0366
- E-post: lpbyatt@salud.unm.edu
-
Albuquerque, New Mexico, Forente stater, 87131
- Rekruttering
- The University of New Mexico Comprehensive Cancer Center
-
Hovedetterforsker:
- Bernard Tawfik, MD
-
Ta kontakt med:
- Sheri Westgate, RN-BSN, OCN
- Telefonnummer: (505) -925-0383
- E-post: swestgate@salud.unm.edu
-
Las Cruces, New Mexico, Forente stater, 88011
- Rekruttering
- Memorial Medical Center
-
Hovedetterforsker:
- Bernard Tawfik, MD
-
Ta kontakt med:
- Kim Hoffman, RN
- Telefonnummer: (575)- 556-6545
- E-post: kim.hoffman@lpnt.net
-
Rio Rancho, New Mexico, Forente stater, 87124
- Rekruttering
- Presbyterian Rust Medical Center
-
Hovedetterforsker:
- Bernard Tawfik, MD
-
Ta kontakt med:
- Andrea Yost
- Telefonnummer: (505) -253-7878
- E-post: ayost3@phs.org
-
-
New York
-
Lake Success, New York, Forente stater, 11042
- Rekruttering
- Northwell Health Monter Cancer Center
-
Ta kontakt med:
- Mary Agnes Templeton
- Telefonnummer: 516-734-8979
- E-post: mtempleton@northwell.edu
-
Hovedetterforsker:
- Marina Frimer, MD
-
Mount Kisco, New York, Forente stater, 10549
- Rekruttering
- Northern Westchester Hospital
-
Hovedetterforsker:
- Marina Frimer, MD
-
Ta kontakt med:
- Jemima Jacob, MPH
- Telefonnummer: 914-666-1366
- E-post: jjacob22@northwell.edu
-
New Hyde Park, New York, Forente stater, 11040
- Rekruttering
- Cohen Children's Medical Center
-
Ta kontakt med:
- Shreya Seepersaud
- Telefonnummer: 718-470-7146
- E-post: sseepersaud2@northwell.edu
-
Hovedetterforsker:
- Marina Frimer, MD
-
New York, New York, Forente stater, 10065
- Rekruttering
- Manhattan Eye, Ear, and Throat Hospital
-
Hovedetterforsker:
- Marina Frimer, MD
-
Ta kontakt med:
- Leila Nasr
- E-post: lnasr@northwell.edu
-
New York, New York, Forente stater, 10305
- Rekruttering
- Staten Island University Hospital
-
Hovedetterforsker:
- Marina Frimer, MD
-
Ta kontakt med:
- Sammi Ruan
- Telefonnummer: 718-226-1489
- E-post: sruan2@northwell.edu
-
Ta kontakt med:
- Melissa McCarthy
- Telefonnummer: 718-226-1805
- E-post: mccarthy22@northwell.edu
-
Rego Park, New York, Forente stater, 11374
- Rekruttering
- Queens Cancer Center
-
Hovedetterforsker:
- Marina Frimer, MD
-
Ta kontakt med:
- Harmandeep Kaur
- Telefonnummer: 718-412-0773
- E-post: hkaur37@northwell.edu
-
Sleepy Hollow, New York, Forente stater, 10591
- Rekruttering
- Phelps Hospital
-
Hovedetterforsker:
- Marina Frimer, MD
-
Ta kontakt med:
- Barbara Turner, RN
- Telefonnummer: 914-269-1949
- E-post: Bturner1@northwell.edu
-
Ta kontakt med:
- Shyrley Gomez
- E-post: Sgomez21@northwell.edu
-
-
North Carolina
-
Chapel Hill, North Carolina, Forente stater, 27599
- Rekruttering
- Lineberger Comprehensive Cancer Center
-
Hovedetterforsker:
- Shetal Patel, MD
-
Ta kontakt med:
- Emmie Cole
- Telefonnummer: 919-966-4432
- E-post: emmie_cole@med.unc.edu
-
Charlotte, North Carolina, Forente stater, 28277
- Rekruttering
- Atrium Health's Levine Cancer Institute
-
Hovedetterforsker:
- Kathryn F. Mileham, MD, FACP
-
Ta kontakt med:
- Jenna Gregory, MS, RN
- E-post: Jenna.Gregory@atriumhealth.org
-
-
North Dakota
-
Bismarck, North Dakota, Forente stater, 58501
- Rekruttering
- Sanford Health- Bismarck
-
Ta kontakt med:
- Peter Kurniali, MD
- Telefonnummer: 701-323-5741
- E-post: peter.kurniali@sanfordhealth.org
-
Hovedetterforsker:
- Peter Kurniali, MD
-
Fargo, North Dakota, Forente stater, 58122
- Rekruttering
- Sanford Health- Fargo
-
Ta kontakt med:
- Anu Gaba, MD
- Telefonnummer: 701-234-6161
- E-post: anu.gaba@sanfordhealth.org
-
Hovedetterforsker:
- Anu Gaba, MD
-
-
Ohio
-
Cincinnati, Ohio, Forente stater, 45219
- Rekruttering
- University of Cincinnati Medical Center
-
Hovedetterforsker:
- Davendra Sohal, MD
-
Ta kontakt med:
- Kayla Webb, MSN, RN
- Telefonnummer: 513-584-0599
- E-post: webb2ka@ucmail.uc.edu
-
Kettering, Ohio, Forente stater, 45429
- Rekruttering
- Kettering Health
-
Ta kontakt med:
- Allison Dymacek, BSN, RN
- Telefonnummer: 937-395-8367
- E-post: allison.dymacek@ketteringhealth.org
-
Hovedetterforsker:
- Lex Leonhardt, DO
-
West Chester, Ohio, Forente stater, 45069
- Rekruttering
- West Chester Hospital
-
Hovedetterforsker:
- Trisha Wise-Draper, MD
-
Ta kontakt med:
- Kayla Webb, MSN, RN
- Telefonnummer: 513-584-0599
- E-post: webb2ka@ucmail.uc.edu
-
-
Oregon
-
Portland, Oregon, Forente stater, 97213
- Rekruttering
- Providence Health & Services
-
Hovedetterforsker:
- Evthokia Hobbs, MD
-
Ta kontakt med:
- Isa Ngirailemesang
- Telefonnummer: 971-358-2056
- E-post: Isa.Ngirailemesang@providence.org
-
-
Pennsylvania
-
Allentown, Pennsylvania, Forente stater, 18103
- Rekruttering
- Lehigh Valley Hospital - Cedar Crest
-
Ta kontakt med:
- Telefonnummer: 734-712-3671
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Hovedetterforsker:
- Maged Khalil, MD
-
Bethlehem, Pennsylvania, Forente stater, 18017
- Rekruttering
- Lehigh Valley Hospital- Muhlenberg
-
Hovedetterforsker:
- Maged Khalil, MD
-
Ta kontakt med:
- Telefonnummer: 7347127251
- E-post: MCRCwebsitecontactform@trinity-health.org
-
East Stroudsburg, Pennsylvania, Forente stater, 18301
- Rekruttering
- Pocono Medical Center
-
Hovedetterforsker:
- Maged Khalil, MD
-
Ta kontakt med:
- Telefonnummer: 7347127251
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Hazleton, Pennsylvania, Forente stater, 18201
- Rekruttering
- Lehigh Valley Hospital-Hazleton
-
Hovedetterforsker:
- Maged Khalil, MD
-
Ta kontakt med:
- Telefonnummer: 7347127251
- E-post: MCRCwebsitecontactform@trinity-health.org
-
Philadelphia, Pennsylvania, Forente stater, 19111
- Rekruttering
- Fox Chase Cancer Center
-
Hovedetterforsker:
- Margaret von Mehren, MD
-
Ta kontakt med:
- Fathima S Sheriff
- Telefonnummer: 215-728-4094
- E-post: fathima.sheriff@fccc.edu
-
-
South Carolina
-
Bluffton, South Carolina, Forente stater, 29910
- Rekruttering
- SC Cancer Specialists at St. Joseph's/Candler Bluffton
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-post: smiths1@sjchs.org
-
Bluffton, South Carolina, Forente stater, 29910
- Rekruttering
- St. Joseph's/Candler Smith
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-post: smiths1@sjchs.org
-
Bluffton, South Carolina, Forente stater, 29910
- Rekruttering
- Summit Cancer Care at St. Josph's/Candler Bluffton
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-post: smiths1@sjchs.org
-
Hilton Head Island, South Carolina, Forente stater, 29926
- Rekruttering
- South Carolina Cancer Specialists
-
Hovedetterforsker:
- Mark Taylor, MD
-
Ta kontakt med:
- Stephanie Smith, RN, MSN, OCN
- Telefonnummer: 19128195723
- E-post: smiths1@sjchs.org
-
-
South Dakota
-
Sioux Falls, South Dakota, Forente stater, 57104
- Rekruttering
- Sanford Cancer Center Oncology Clinic and Pharmacy
-
Hovedetterforsker:
- Steven Powell, MD
-
Ta kontakt med:
- Steven Powell, MD
- Telefonnummer: 605-328-8000
- E-post: steven.powell@sanfordhealth.org
-
-
Tennessee
-
Nashville, Tennessee, Forente stater, 37203
- Rekruttering
- Tennessee Oncology - Nashville / Sarah Cannon Research Institute
-
Ta kontakt med:
- Ethan Trull
- Telefonnummer: 615-329-7274
- E-post: Ethan.Trull@SarahCannon.com
-
Hovedetterforsker:
- Meredith McKean, MD, MPH
-
-
Texas
-
Houston, Texas, Forente stater, 77030
- Rekruttering
- The University of Texas MD Anderson Cancer Center
-
Hovedetterforsker:
- Funda Meric-Bernstam, MD
-
Ta kontakt med:
- Kshipra Sharma, MPH, MS
- Telefonnummer: 713-745-8431
- E-post: Ksharma2@MDAnderson.org
-
-
Utah
-
Cedar City, Utah, Forente stater, 84720
- Rekruttering
- Cedar City Hospital, SW Cancer Clinic, Sandra Maxwell Cancer Center
-
Hovedetterforsker:
- Ramya Thota, MD
-
Ta kontakt med:
- Jake Kolu
- Telefonnummer: 435-705-1632
- E-post: Jake.Kolu@imail.org
-
Hovedetterforsker:
- Derrick Haslem, MD
-
Salt Lake City, Utah, Forente stater, 84107
- Rekruttering
- Intermountain Healthcare
-
Ta kontakt med:
- Tracy Taylor
- Telefonnummer: 801-507-3953
- E-post: tracy.taylor@imail.org
-
Hovedetterforsker:
- Ramya Thota, M.D.
-
Hovedetterforsker:
- Derrick Haslem, M.D.
-
St. George, Utah, Forente stater, 84770
- Rekruttering
- Dixie Regional Medical Center-River Road Campus
-
Hovedetterforsker:
- Ramya Thota, MD
-
Ta kontakt med:
- Jake Kolu
- Telefonnummer: 435-705-1632
- E-post: Jake.Kolu@imail.org
-
Hovedetterforsker:
- Derrick Haslem, MD
-
-
Virginia
-
Fairfax, Virginia, Forente stater, 22042
- Rekruttering
- Inova Schar Cancer Institute
-
Hovedetterforsker:
- Timothy Cannon, MD
-
Ta kontakt med:
- Roxana Comfort, CRC
- Telefonnummer: 571-472-0628
- E-post: roxana.comfort@inova.org
-
-
Washington
-
Bonney Lake, Washington, Forente stater, 98391
- Rekruttering
- Northwest Medical Specialties
-
Ta kontakt med:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-post: research@southsoundcare.org
-
Hovedetterforsker:
- Frank Senecal, MD
-
Federal Way, Washington, Forente stater, 98003
- Rekruttering
- Northwest Medical Specialties
-
Ta kontakt med:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-post: research@southsoundcare.org
-
Hovedetterforsker:
- Frank Senecal, MD
-
Gig Harbor, Washington, Forente stater, 98332
- Rekruttering
- Northwest Medical Specialties
-
Ta kontakt med:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-post: research@southsoundcare.org
-
Hovedetterforsker:
- Frank Senecal, MD
-
Olympia, Washington, Forente stater, 98502
- Rekruttering
- Northwest Medical Specialties
-
Ta kontakt med:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-post: research@southsoundcare.org
-
Hovedetterforsker:
- Frank Senecal, MD
-
Puyallup, Washington, Forente stater, 98373
- Rekruttering
- Northwest Medical Specialties
-
Hovedetterforsker:
- Frank Senecal, MD
-
Ta kontakt med:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-post: reserch@southsoundcare.org
-
Seattle, Washington, Forente stater, 98104
- Rekruttering
- Swedish Cancer Institute
-
Hovedetterforsker:
- Philip Gold, MD
-
Ta kontakt med:
- Sidney Ching
- Telefonnummer: 206-386-3142
- E-post: sidney.ching@swedish.org
-
Tacoma, Washington, Forente stater, 98405
- Rekruttering
- Northwest Medical Specialties
-
Hovedetterforsker:
- Frank Senecal, MD
-
Ta kontakt med:
- Jennifer Spokely
- Telefonnummer: 253-999-3701
- E-post: reserch@southsoundcare.org
-
-
Wisconsin
-
Burlington, Wisconsin, Forente stater, 53105
- Rekruttering
- Aurora Cancer Care - Burlington
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Germantown, Wisconsin, Forente stater, 53022
- Rekruttering
- Aurora Health Care - Germantown Health Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Grafton, Wisconsin, Forente stater, 53024
- Rekruttering
- Aurora Cancer Care - Grafton
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Green Bay, Wisconsin, Forente stater, 54311
- Rekruttering
- Aurora BayCare Medical Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Kenosha, Wisconsin, Forente stater, 53142
- Rekruttering
- Aurora Cancer Care - Kenosha South
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Marinette, Wisconsin, Forente stater, 54143
- Rekruttering
- Aurora Bay Area Medical Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forente stater, 53215
- Rekruttering
- Aurora St. Luke's Medical Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle M Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forente stater, 53209
- Rekruttering
- Aurora Cancer Care Milwaukee
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle M Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forente stater, 53223
- Rekruttering
- Aurora Sinai Medical Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Milwaukee, Wisconsin, Forente stater, 53227
- Rekruttering
- Aurora West Allis Medical Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Oshkosh, Wisconsin, Forente stater, 54904
- Rekruttering
- Vince Lombardi Cancer Clinic - Oshkosh
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Racine, Wisconsin, Forente stater, 53406
- Rekruttering
- Aurora Cancer Care - Racine
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Sheboygan, Wisconsin, Forente stater, 53081
- Rekruttering
- Vince Lombardi Cancer Center
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Summit, Wisconsin, Forente stater, 53066
- Rekruttering
- Aurora Medical Center in Summit
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Two Rivers, Wisconsin, Forente stater, 54241
- Rekruttering
- Vince Lombardi Cancer Clinic - Two Rivers
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 9204567880
- E-post: Michelle.Martin2@aah.org
-
Wauwatosa, Wisconsin, Forente stater, 53226
- Rekruttering
- Aurora Cancer Care - Milwaukee West
-
Hovedetterforsker:
- Antony Ruggeri, MD
-
Ta kontakt med:
- Michelle Toutloff, RN, CCRP
- Telefonnummer: 920-456-7880
- E-post: Michelle.Martin2@aah.org
-
-
-
-
Puerto Rico
-
Cayey, Puerto Rico, Puerto Rico, 00737
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Cruz Correa, MD
-
Dorado, Puerto Rico, Puerto Rico, 00646
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Cruz Correa, MD
-
Manati, Puerto Rico, Puerto Rico, 00674
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Crus Correa, MD
-
Mayagüez, Puerto Rico, Puerto Rico, 00680
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Cruz Correa, MD
-
Ponce, Puerto Rico, Puerto Rico, 00730
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Puerto Rico, 00909
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Cruz Correa, MD
-
San Juan, Puerto Rico, Puerto Rico, 00935
- Rekruttering
- PanOncology Trials
-
Ta kontakt med:
- Natalia Ortiz
- Telefonnummer: 787-407-3333
- E-post: natalia.ortiz@panoncologytrials.com
-
Hovedetterforsker:
- Maria Cruz Correa, MD
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
-
12 years of age or older (*Restrictions apply. Not all therapies are available for patients <18)
-
Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated (except under the circumstance in which the TAPUR arm is designed to provide additional evidence to support an existing FDA indication).
-
Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)
-
Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion/exclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:
- Absolute neutrophil count ≥ 1500 µl
- Hemoglobin ≥ 9.0 g/dl
- Platelets ≥ 75,000/µl
- Total bilirubin < 2.0 mg/ dl, except in patients with Gilbert's Syndrome
- Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) < 2.5 x institutional upper limit of normal (ULN) (or < 5 x ULN in patients with known hepatic metastases)
- Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL/min/1.73 m2
-
Patients must have disease that can be objectively measured by physical, laboratory or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma).
-
Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma ("liquid biopsies") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.
-
Ability to understand and the willingness to sign a written informed consent/assent document.
-
Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.
-
For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.
-
Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study treatment, or completely abstain from sexual intercourse.
Note: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.
Exclusion Criteria:
- Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible
- Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded
- Patients with previously treated brain metastases or previously treated leptomeningeal disease are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 1 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.
- Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.
Note: there are additional exclusion criteria that may apply
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Annen: Group 5 (CSF1R,PDGFR,VEGFR)
Participants receive sunitinib - dosage, frequency and duration per label; acceptable genomic matches include CSF1R, PDGFR, VEGFR1/2/3, KIT, FLT-3, RET, FGFR1/2/3, VHL amplifications or mutations |
drug
Andre navn:
|
|
Annen: Group 8 (ERBB2)
Participants receive trastuzumab and pertuzumab - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Andre navn:
|
|
Annen: Group 9 (BRAF V600E/D/K/R)
Participants receive vemurafenib and cobimetinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600E/D/K/R mutations |
drug
Andre navn:
|
|
Annen: Group 14 (BRCA1/2; ATM)
Participants receive olaparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 inactivating mutations; ATM mutations or deletions |
drug
Andre navn:
|
|
Annen: Group 16 (MSI-H, high mutational load and others)
Participants receive nivolumab and ipilimumab - dosage, frequency and duration per label; acceptable genomic matches include MSI high status, high tumor mutational burden, MLH1, MSH2/6, PMS2, EPCAM mutations, specific POLE or POLD1 mutations, BRCA1/2, ATM, MSH3, PMS1, MLH3, EXO1, RFC1/2/3/4/5, PCNA, RPA1/2/3/4, and SSBP1 loss of function mutations |
drug
Andre navn:
|
|
Annen: Group 17 (CDKN2A, CDK4, CDK6)
Participants receive abemaciclib - dosage, frequency and duration per label; acceptable genomic matches include CDKN2A loss or mutation, CDK4, CDK6 amplifications, CDKN2B loss or mutation |
drug
Andre navn:
|
|
Annen: Group 19 (BRCA1/2, PALB2)
Participants receive talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic BRCA1/2 and PALB2 mutations |
drug
Andre navn:
|
|
Annen: Group 21 (BRCA1/2, PALB2, ATM, and others)
Participants receive atezolizumab plus talazoparib - dosage, frequency and duration per label; acceptable genomic matches include germline or somatic mutations in BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN, MLH1, MRE11A, CDK12; positive genomic instability score reported on the Myriad MyChoice CDx test; or Genomic Loss of Heterozygosity (LOH) Score above threshold as reported on a FoundationOne CDx test or another qualifying test for TAPUR with MTB approval |
drug
Andre navn:
|
|
Annen: Group 24 (ERBB2)
Participants receive tucatinib plus trastuzumab SC - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification or overexpression, and specific ERBB2 mutations |
drug
Andre navn:
|
|
Annen: Group 25
Participants receive futibatinib- dosage, frequency and duration per label; acceptable genomic matches include FGFR 1,2,3,4 fusion (or other rearrangement) or mutation |
drug
Andre navn:
|
|
Annen: Group 26 (BRAF V600 E mutation )
Participants receive Dabrafenib plus Trametinib - dosage, frequency and duration per label; acceptable genomic matches include BRAF V600 E mutation . |
Drug
Andre navn:
|
|
Annen: Group 27 (ERBB2 amplification, ERBB2 (HER2) IHC2+ or IHC3+ overexpression)
Participants receive Fam-trastuzumab deruxtecan-nxki (ENHERTU®) - dosage, frequency and duration per label; acceptable genomic matches include ERBB2 amplification, For NSCLC Only-ERBB2 (HER2) IHC2+ or IHC3+ overexpression without ERBB2 amplification) |
Drug
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective Response Rate defined as % of participants in a cohort with complete or partial response or with stable disease according to standard response criteria
Tidsramme: Assessed at 16 weeks of treatment
|
Each cohort includes participants with the same tumor type, genomic variant and study drug. For solid tumors, the Response Evaluation Criteria for Solid Tumors (RECIST) criteria will be used, for non-Hodgkin Lymphoma, the Lugano Criteria will be used, and for multiple myeloma, the International Uniform Response Criteria for Multiple Myeloma will be used. |
Assessed at 16 weeks of treatment
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Overall survival (OS)
Tidsramme: Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
OS will be estimated using the Kaplan-Meier method |
Duration of survival from registration on study until death from any cause, assessed throughout end of study, up to 3 years
|
Samarbeidspartnere og etterforskere
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Alva AS, Mangat PK, Garrett-Mayer E, Halabi S, Hansra D, Calfa CJ, Khalil MF, Ahn ER, Cannon TL, Crilley P, Fisher JG, Haslem DS, Shrestha S, Antonelli KR, Butler NL, Warren SL, Rygiel AL, Ranasinghe S, Bruinooge SS, Schilsky RL. Pembrolizumab in Patients With Metastatic Breast Cancer With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. J Clin Oncol. 2021 Aug 1;39(22):2443-2451. doi: 10.1200/JCO.20.02923. Epub 2021 Apr 12.
- Fisher JG, Tait D, Garrett-Mayer E, Halabi S, Mangat PK, Schink JC, Alvarez RH, Veljovich D, Cannon TL, Crilley PA, Pollock T, Calfa CJ, Al Baghdadi T, Thota R, Fleming N, Cotta JA, Rygiel AL, Warren SL, Schilsky RL. Cetuximab in Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Ovarian Cancer Without KRAS, NRAS, or BRAF Mutations: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):733-741. doi: 10.1007/s11523-020-00753-7.
- Al Baghdadi T, Garrett-Mayer E, Halabi S, Mangat PK, Rich P, Ahn ER, Chai S, Rygiel AL, Osayameh O, Antonelli KR, Islam S, Bruinooge SS, Schilsky RL. Sunitinib in Patients with Metastatic Colorectal Cancer (mCRC) with FLT-3 Amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. Target Oncol. 2020 Dec;15(6):743-750. doi: 10.1007/s11523-020-00752-8.
- Gupta R, Meric-Bernstam F, Rothe M, Garrett-Mayer E, Mangat PK, D'Andre S, Ahn ER, O'Lone R, Halabi S, Grantham GN, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With ERBB2 Amplification or ERBB2/3 Mutations: Results From the TAPUR Study. JCO Precis Oncol. 2022 Oct;6:e2200306. doi: 10.1200/PO.22.00306.
- Mangat PK, Kirkwood MK, Hinshaw DC, Garrett-Mayer E, Schilsky RL. Prevalence of targetable genomic alterations among a diverse population participating in the ASCO TAPUR Study. NPJ Precis Oncol. 2025 Jul 3;9(1):222. doi: 10.1038/s41698-025-00962-1.
- Worden FP, Pisick E, Rothe M, Mangat PK, Garrett-Mayer E, Khalil MF, Carrizosa DR, Bauman JR, Leidner RS, Duvivier HL, Fu S, Park MS, Yost KJ, Calfa CJ, Marr AS, Balmanoukian AS, Behl D, Cannon TL, Nabell L, Powell SF, Thota R, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Oct;8:e2400477. doi: 10.1200/PO-24-00477. Epub 2024 Oct 16.
- Schuetze S, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Calfa CJ, Farrington LC, Livingston MB, Wentzel K, Behl D, Kier Y, Marr AS, von Mehren M, Press JZ, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jul;8:e2400219. doi: 10.1200/PO.24.00219.
- Srkalovic G, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Brouse G, Chan J, Mehmi I, Khalil M, Duvivier HL, Gaba A, Leuva H, Thota R, Yost KJ, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Talazoparib in Patients With Solid Tumors With BRCA1/2 Mutation: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Jun;8:e2400026. doi: 10.1200/PO.24.00026.
- Cannon TL, Rothe M, Mangat PK, Garrett-Mayer E, Chiu VK, Hwang J, Vijayvergia N, Alese OB, Dib EG, Duvivier HL, Klute KA, Sahai V, Ahn ER, Bedano P, Behl D, Sinclair S, Thota R, Urba WJ, Yang ES, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Biliary Tract Cancer With ERBB2/3 Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2024 Sep 20;42(27):3228-3237. doi: 10.1200/JCO.23.02078. Epub 2024 May 15.
- Perez JK, Kleber J, Rothe M, Mangat P, Garrett-Mayer E, Schilsky RL. Concordance in Molecular Tumor Board Case Reviews in the ASCO TAPUR Study. JCO Precis Oncol. 2024 Mar;8:e2300615. doi: 10.1200/PO.23.00615.
- Calfa CJ, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Burness ML, Gogineni K, Rohatgi N, Al Baghdadi T, Conlin A, Gaba A, Hamid O, Krishnamurthy J, Gavini NJ, Gold PJ, Rodon J, Rueter J, Thota R, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Sunitinib in Patients With Breast Cancer With FGFR1 or FGFR2 Amplifications or Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2024 Feb;8:e2300513. doi: 10.1200/PO.23.00513.
- Meric-Bernstam F, Rothe M, Mangat PK, Garrett-Mayer E, Gutierrez R, Ahn ER, Cannon TL, Powell S, Krauss JC, Reynolds CM, von Mehren M, Behl D, Calfa CJ, Duvivier HL, Kaplan HG, Livingston MB, Sharma MR, Urba WJ, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Cobimetinib Plus Vemurafenib in Patients With Solid Tumors With BRAF Mutations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Sep;7:e2300385. doi: 10.1200/PO.23.00385.
- Rohatgi N, Rothe M, Mangat PK, Garrett-Mayer E, Meric-Bernstam F, Pisick E, Alese OB, Reynolds CM, Thota R, Vaccaro GM, von Mehren M, Arend RC, Chiu VK, Duvivier HL, Gold PJ, Hack K, Marr AS, Winer A, Grantham GN, Hinshaw DC, Gregory A, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With ATM Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2023 Sep;7:e2300279. doi: 10.1200/PO.23.00279.
- Duvivier HL, Rothe M, Mangat PK, Garrett-Mayer E, Ahn ER, Al Baghdadi T, Alva AS, Dublis SA, Cannon TL, Calfa CJ, Li R, Behl D, Chiu VK, Gold PJ, Marr AS, Mileham KF, Powell SF, Rodon J, Thota R, Grantham GN, Gregory A, Hinshaw DC, Halabi S, Schilsky RL. Pembrolizumab in Patients With Tumors With High Tumor Mutational Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. J Clin Oncol. 2023 Nov 20;41(33):5140-5150. doi: 10.1200/JCO.23.00702. Epub 2023 Aug 10.
- Mangat PK, Garrett-Mayer E, Perez JK, Schilsky RL. The Targeted Agent and Profiling Utilization Registry Study: A pragmatic clinical trial. Clin Trials. 2023 Dec;20(6):699-707. doi: 10.1177/17407745231182013. Epub 2023 Jul 25.
- Ganti AK, Rothe M, Mangat PK, Garrett-Mayer E, Dib EG, Duvivier HL, Ahn ER, Behl D, Borghaei H, Balmanoukian AS, Gaba A, Li R, Osei-Boateng K, Thota R, Grantham GN, Gregory A, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2023 Jun;7:e2300041. doi: 10.1200/PO.23.00041.
- Ahn ER, Rothe M, Mangat PK, Garrett-Mayer E, Ali-Ahmad HM, Chan J, Maitland ML, Patel SR, Reese Z, Balmanoukian AS, Drescher CW, Li R, Tsimberidou AM, Leath CA 3rd, O'Lone R, Grantham GN, Halabi S, Schilsky RL. Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Apr;7:e2200609. doi: 10.1200/PO.22.00609.
- Yang ES, Halabi S, Rothe M, Garrett-Mayer E, Mangat PK, Pisick E, Dib E, Burgess EF, Zakem M, Rohatgi N, Bilen MA, O'Lone R, Grantham GN, Schilsky RL. Olaparib in Patients With Metastatic Prostate Cancer With BRCA1/2 Mutation: Results From the TAPUR Study. JCO Precis Oncol. 2023 Feb;7:e2200505. doi: 10.1200/PO.22.00505.
- Carrizosa DR, Rothe M, Mangat PK, Garrett-Mayer E, Behl D, Adesunloye B, Pisick E, Beekman KW, Dotan E, Akce M, Alese OB, Sahai V, Klute KA, Aragon-Ching JB, Cooper KA, Thota R, Meric-Bernstam F, Hosein PJ, Maestas EC, Moyers JT, Powell S, Zhao S, Hobbs E, Rueter J, Sohal DPS, Taylor MA, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Jan;10:e2500716. doi: 10.1200/PO-25-00716. Epub 2026 Jan 15.
- Al Baghdadi T, Rothe M, Mangat PK, Garrett-Mayer E, Crysler OV, Mileham KF, Farrington LC, Adesunloye B, Dublis SA, Astsaturov I, Calfa CJ, Bleeker J, Khalil M, Thota R, Cannon TL, Alese OB, Gold PJ, Hafez N, Baron AD, Meric-Bernstam F, Hobbs E, Marr AS, Rueter J, Tawfik B, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Olaparib in Patients With Solid Tumors With BRCA1/2 Alterations: Results From The Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2025 Oct;9:e2500649. doi: 10.1200/PO-25-00649. Epub 2025 Oct 16.
- Cobain EF, Rothe M, Garrett-Mayer E, Cannon TL, Chan JK, Mileham KF, Adesunloye B, Calfa CJ, Alese OB, Butler KY, Dib EG, Pisick E, Bell M, Klute KA, Mehmi I, Meric-Bernstam F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Nivolumab Plus Ipilimumab in Patients With Solid Tumors With High Tumor Mutation Burden: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Apr;10(4):e2501205. doi: 10.1200/PO-25-01205. Epub 2026 Apr 30.
- Pisick E, Rothe M, Garrett-Mayer E, Srkalovic G, Chan JK, Calfa CJ, Leath CA 3rd, Marr AS, Gold PJ, Crane EK, Moyers JT, Yost Butler K, Gaba A, Thota R, Harnden KK, Alese OB, Jain A, Rueter J, Gill S, George TJ, Frimer M, Kayali F, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Temsirolimus in Patients With Solid Tumors With PIK3CA Mutations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Apr;10(4):e2500985. doi: 10.1200/PO-25-00985. Epub 2026 Apr 22.
- Veljovich DS, Rothe M, Garrett-Mayer E, Ali-Ahmad HM, Naumann RW, Siedel J, Chan JK, Gregory A, Pisick E, Adesunloye B, Arend RC, Bell M, Frimer M, Tawfik B, Thota R, Tsimberidou AM, Mangat PK, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Palbociclib in Patients With Ovarian Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study. JCO Precis Oncol. 2026 Jul;10(7):e2600456. doi: 10.1200/PO-26-00456. Epub 2026 Jul 15.
- Diamond-Rossi SA, Rothe M, Garrett-Mayer E, Pisick E, Bleeker J, Ganti AK, Meric-Bernstam F, Moyers JT, Nair SG, Kadakia KC, Rohatgi N, Sahai V, Vijayvergia N, Gold PJ, Sharma MR, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Cobimetinib + Vemurafenib in Patients With BRAF V600E-Mutant Papillary Thyroid and Biliary Tract Cancers: Results From the TAPUR Study. JCO Precis Oncol. 2026 Oct;10(10):e2600703. doi: 10.1200/PO-26-00703. Epub 2026 Oct 16.
- Srkalovic G, Rothe M, Garrett-Mayer E, Mileham KF, Adesunloye B, Pisick E, Leath CA 3rd, Colocci N, Chen MD, Meric-Bernstam F, Marr AS, Alese OB, Powell S, Rueter J, Benyounes A, Pontious C, Lewis MA, Thomas GW, Kier Y, Calfa CJ, von Mehren M, Acoba JD, Hinshaw DC, Gregory A, Grantham GN, Halabi S, Schilsky RL. Sunitinib in Patients With Various Solid Tumors With FGFR1/2 Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study. JCO Precis Oncol. 2026 Oct;10(10):e2600454. doi: 10.1200/PO-26-00454. Epub 2026 Oct 7.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Antatt)
Studiet fullført (Antatt)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Antatt)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Vaskulære sykdommer
- Kardiovaskulære sykdommer
- Sykdommer i immunsystemet
- Neoplasmer etter histologisk type
- Hematologiske sykdommer
- Lymfesykdommer
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Lymfom
- Neoplasmer, plasmacelle
- Hemostatiske lidelser
- Paraproteinemier
- Blodproteinforstyrrelser
- Hemoragiske lidelser
- Hemic og lymfatiske sykdommer
- Neoplasmer
- Multippelt myelom
- Lymfom, Non-Hodgkin
- Aminosyrer, peptider og proteiner
- Proteiner
- Svovelforbindelser
- Organiske kjemikalier
- Heterocykliske forbindelser, 1-ring
- Heterocykliske forbindelser
- Heterocykliske forbindelser, 2-ring
- Heterocykliske forbindelser, smeltet ringen
- Azoler
- Amides
- Indoler
- Antistoffer, monoklonalt, humanisert
- Antistoffer, monoklonalt
- Antistoffer
- Immunoglobuliner
- Immunoproteiner
- Blodproteiner
- Serumglobuliner
- Globuliner
- Pyrroles
- Sulfonamider
- Sulfoner
- Trastuzumab
- Sunitinib
- Nivolumab
- Ipilimumab
- Vemurafenib
- Abemaciclib
- Pertuzumab
- Dabrafenib
- trametinib
- Atezolizumab
- olaparib
- Talazoparib
- kobimetinib
- Tucatinib
- Futibatinib
Andre studie-ID-numre
- Pro00014171
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .